Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRACTICAL study of cobicistat-boosted tofacitinib dose reduction in rheumatoid or psoriatic arthritis
NL-OMON48994Phase 2Active, not recruiting
- Sponsor
- Radboud University Medical Center
- Start
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tofacitinib and cobicistat in rheumatoid arthritis (RA) and psoriatic arthritis (PsA), sponsored by Radboud University Medical Center. Primary endpoint: Bioequivalence of boosted once-daily tofacitinib versus standard twice-daily tofacitinib. Started Sep 2019; status: active, not recruiting.
02
Drugs
tofacitinibcobicistat
03
Conditions
rheumatoid arthritis (RA)psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NL-OMON48994.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48994.